Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05626621 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis
A Phase 4 study of Chronic Rhinitis, sponsored by Endeavor Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT05626621: Recruiting Phase 4 study of Chronic Rhinitis, sponsored by Endeavor Health.
NCT05626621 is a Phase 4 study of Chronic Rhinitis that is actively recruiting participants, run by Endeavor Health. The registered enrollment target is 81 participants, roughly in line with the 84-participant average among 6 other Chronic Rhinitis trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05626621, a Phase 4 study of Chronic Rhinitis, is actively recruiting participants, sponsored by Endeavor Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine the best combination of drugs and drug delivery routes to treat surgically naive chronic rhinitis patients. The main question it aims to answer is: Do high volume, high pressure delivery mechanisms in nasal irrigation improve the efficacy of azelastine combined with nasal steroid mometasone as compared to the standard low pressure, low volume delivery mechanisms in nasal sprays? Subjects will complete six months of one of three medication regimens: 1. Saline irrigation followed by azelastine spray and mometasone spray 2. Mometasone saline irrigation 3. Azelastine saline irrigation combined with mometasone saline irrigation.
Conditions Studied
Interventions
- DRUG Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray
- DRUG Mometasone Nasal Irrigation (1 mg capsule)
- DRUG Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation
Study Locations (1)
Illinois
- Northshore University HealthSystem - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2022-11-23 |
| Est. Completion | 2026-08 |
| Phase | Phase 4 |
What NCT05626621 shows while recruiting
NCT05626621 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, roughly in line with the 84-participant average among 6 other Chronic Rhinitis trials with a reported enrollment target.
The record links to 1 condition, with Chronic Rhinitis appearing as the primary indexed condition, and to 3 interventions - of which Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray is the first listed.
NCT05626621 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05626621 about?
NCT05626621 is a clinical study titled "Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis". The goal of this clinical trial is to determine the best combination of drugs and drug delivery routes to treat surgically naive chronic rhinitis patients. The main question it aims to answer is: Do high volume, high pressure delivery mechanisms in nasal irrigation improve the efficacy of azelastin...
What is the current status of trial NCT05626621?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2022-11-23. Estimated completion is 2026-08.
What conditions does trial NCT05626621 study?
This clinical trial studies the following conditions: Chronic Rhinitis.
What interventions are being tested in trial NCT05626621?
The interventions under investigation include: Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray (DRUG), Mometasone Nasal Irrigation (1 mg capsule) (DRUG), Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation (DRUG).
Who is sponsoring clinical trial NCT05626621?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05626621 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of RhinAer Stylus for Treating Chronic Rhinitis
ACTIVE NOT RECRUITING · NA
-
NEUROMARK Registry Study
ACTIVE NOT RECRUITING · NA
-
Multi-Treatment PNN Modulation for Chronic Rhinitis
COMPLETED · NA
-
ClariFix Rhinitis RCT
COMPLETED · NA
-
Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis (CLARITY)
COMPLETED · NA
-
A Study of RhinAer ARC Stylus for Treating Chronic Rhinitis (RELIEF)
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI